|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
|
US7695725B2
(en)
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
PT1592441E
(pt)
|
2003-02-06 |
2012-05-21 |
Aduro Biotech |
Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
|
|
WO2004084936A2
(en)
|
2003-02-06 |
2004-10-07 |
Cerus Corporation |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
AU2004229543A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Medimmune, Llc |
EphA2 and non-neoplastic hyperproliferative cell disorders
|
|
US7842289B2
(en)
*
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
|
WO2006034334A2
(en)
|
2004-09-21 |
2006-03-30 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
|
|
AU2005295158A1
(en)
*
|
2004-10-18 |
2006-04-27 |
Medimmune, Llc |
High cell density process for growth of Listeria
|
|
WO2006047638A2
(en)
*
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
|
|
DE102006004612A1
(de)
*
|
2006-02-01 |
2007-08-16 |
Ralf Dr. med. Jochem |
Therapeutische Zusammensetzung zur Vorbeugung und Bekämpfung von Knochenmetastasen
|
|
EP1991263B8
(en)
|
2006-03-01 |
2015-02-25 |
Aduro Biotech |
Engineered listeria and methods of use thereof
|
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
|
US7935804B2
(en)
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
|
WO2007103261A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Medimmune, Inc. |
Listeria-based epha2 immunogenic compositions
|
|
US8926993B2
(en)
*
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
|
PT2977456T
(pt)
*
|
2006-08-15 |
2018-02-05 |
Univ Pennsylvania |
Composições compreendendo hmw-maa e seus fragmentos para tratamento do cancro
|
|
US8268326B2
(en)
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
|
BRPI0816094A2
(pt)
|
2007-08-30 |
2015-03-03 |
Daiichi Sankyo Co Ltd |
Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
|
|
WO2009044272A2
(en)
*
|
2007-10-04 |
2009-04-09 |
000'npt Mbp Gormezis' |
Laser-based vaccine adjuvants
|
|
US9017660B2
(en)
*
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
|
US20140234370A1
(en)
*
|
2009-11-11 |
2014-08-21 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
|
|
CN102076843A
(zh)
|
2008-05-19 |
2011-05-25 |
艾杜罗生物科技公司 |
包含prfa*突变体李斯特菌的组合物及其使用方法
|
|
WO2010071769A2
(en)
*
|
2008-12-12 |
2010-06-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Chimeric l. monocytogens in1b protein
|
|
JP5539411B2
(ja)
|
2009-03-04 |
2014-07-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
血管新生因子を含む組成物およびその使用方法
|
|
EP2498808A4
(en)
*
|
2009-11-11 |
2014-01-08 |
Advaxis |
COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
CN103237901B
(zh)
|
2010-03-01 |
2016-08-03 |
卡里斯生命科学瑞士控股有限责任公司 |
用于治疗诊断的生物标志物
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
WO2011149852A1
(en)
|
2010-05-23 |
2011-12-01 |
Aduro Biotech |
Methods and compositions using listeria for adjuvant treatment of cancer
|
|
GB2482536B
(en)
|
2010-08-05 |
2013-07-24 |
Hera Pharmaceuticals Inc |
Expression of antibody or a fragment thereof in lactobacillus
|
|
EP4159226A1
(en)
*
|
2010-08-24 |
2023-04-05 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
|
|
EP2446895A1
(en)
*
|
2010-10-01 |
2012-05-02 |
Stemgen S.P.A. |
EPH receptor expression in tumor stem cells
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
|
EP2764082B1
(en)
*
|
2011-10-04 |
2018-05-23 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
EP2825195A4
(en)
|
2012-03-12 |
2015-10-07 |
Advaxis Inc |
INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
|
|
HUE056350T2
(hu)
|
2012-05-16 |
2022-02-28 |
Stemline Therapeutics Inc |
Rákos õssejt célzott rák elleni vakcinák
|
|
AU2013271375B2
(en)
|
2012-06-08 |
2018-03-22 |
Aduro Biotech, Inc. |
Compositions and methods for cancer immunotherapy
|
|
HK1213008A1
(zh)
|
2012-11-06 |
2016-06-24 |
艾杜罗生物科技公司 |
兼性减毒细菌种类及其制备和使用方法
|
|
AU2013358892B2
(en)
|
2012-12-13 |
2018-06-21 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
SG10201700916SA
(en)
|
2012-12-27 |
2017-03-30 |
Aduro Biotech Inc |
Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
|
|
ES2822584T3
(es)
|
2013-05-03 |
2021-05-04 |
Univ California |
Inducción de dinucleótidos cíclicos del interferón tipo I
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
SG11201609135VA
(en)
*
|
2014-05-02 |
2016-11-29 |
Univ Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
|
|
US10925945B2
(en)
|
2014-10-13 |
2021-02-23 |
Providence Health & Services-Oregon |
Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
|
|
US20160228530A1
(en)
*
|
2014-10-14 |
2016-08-11 |
The Trustees Of The University Of Pennsylvania |
Combination therapy for use in cancer therapy
|
|
US10688166B2
(en)
|
2014-11-03 |
2020-06-23 |
Cerus Corporation |
Compositions and methods for improved car-T cell therapies
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
EA201890149A1
(ru)
|
2015-06-26 |
2018-07-31 |
Сирус Корпорейшн |
Композиции криопреципитатов и способы их получения
|
|
US10799533B2
(en)
|
2015-10-23 |
2020-10-13 |
Cerus Corporation |
Plasma compositions and methods of use thereof
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
AU2017382449B2
(en)
|
2016-12-23 |
2024-10-24 |
Cerus Corporation |
Systems and methods for testing and screening using compound bound substrates
|
|
BR112019018273A2
(pt)
|
2017-03-03 |
2020-07-14 |
Cerus Corporation |
kits e métodos para preparação de composições de plaquetas inativadas por patógenos
|
|
TWI821233B
(zh)
|
2017-12-29 |
2023-11-11 |
美商西勒斯股份有限公司 |
用於處理生物流體之方法、藉由該方法製備之病原體去活生物流體、及用於處理生物流體之系統
|
|
CA3143213A1
(en)
|
2019-06-22 |
2020-12-30 |
Cerus Corporation |
Biological fluid treatment systems
|
|
WO2020264421A1
(en)
|
2019-06-28 |
2020-12-30 |
Cerus Corporation |
System and methods for implementing a biological fluid treatment device
|
|
CN114015644A
(zh)
*
|
2021-11-05 |
2022-02-08 |
成都生物制品研究所有限责任公司 |
一种单一病毒收获液的生产方法
|
|
CN114848654B
(zh)
*
|
2022-04-18 |
2024-04-05 |
武汉大学 |
阿司匹林在制备用于引起肿瘤免疫原性细胞死亡的药物中的应用
|